A. Lackenby

发表

Neuraminidase Receptor Binding Variants of Human Influenza A(H3N2) Viruses Resulting from Substitution of Aspartic Acid 151 in the Catalytic Site: a Role in Virus Attachment?

P. Collins, S. Wharton, A. Hay, 2010, Journal of Virology.

Viruses due to Substitution of Aspartic acid 151 in the Catalytic Site – Role in Virus Attachment ?

P. Collins, S. Wharton, A. Hay, 2010 .

Isolation of an Intertypic Poliovirus Capsid Recombinant from a Child with Vaccine-Associated Paralytic Poliomyelitis

A. Heath, A. Lackenby, Javier Martin, 2002, Journal of Virology.

Early seasonal influenza vaccination and delayed influenza peaks - A possible cause of end-of-season outbreaks.

J. Tang, M. Galiano, J. Ellis, 2018, The Journal of infection.

Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.

C Moore, R. Pebody, M. Galiano, 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.

Maria Zambon, Masato Tashiro, Adam Meijer, 2012, The Lancet. Infectious diseases.

Self-sampling for community respiratory illness: a new tool for national virological surveillance.

D. Fleming, A. Charlett, A. Elliot, 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy

C. Giaquinto, A. Lackenby, S. Esposito, 2010, Virology Journal.

Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season

J. van de Kassteele, J. Paget, B. Lina, 2009, Emerging infectious diseases.

Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013.

B. Sibal, R. Pebody, R. Myers, 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18

S. de Lusignan, R. Pebody, M. Galiano, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Oseltamivir-Resistant Infl uenza Viruses A ( H 1 N 1 ) , Norway , 2007 – 08

A. Lackenby, K. Borgen, S. Hauge, 2009 .

Rapid Quantitation of Neuraminidase Inhibitor Drug Resistance in Influenza virus Quasispecies

M. Zambon, A. Lackenby, M. Siqueira, 2008, Antiviral therapy.

The mechanism of resistance to favipiravir in influenza

D. Goldhill, W. Barclay, M. Zambon, 2018, Proceedings of the National Academy of Sciences.

Clinical and socioeconomic impact of different types and subtypes of seasonal influenza viruses in children during influenza seasons 2007/2008 and 2008/2009

C. Giaquinto, A. Lackenby, S. Esposito, 2011, BMC infectious diseases.

Cross sectional investigation of a COVID-19 outbreak at a London Army barracks: Neutralising antibodies and virus isolation

R. Myers, N. Andrews, S. Ladhani, 2020, The Lancet Regional Health - Europe.

Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.

F. Pozo, I. Casas, A. Lackenby, 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Surveillance and outbreak reports Y 155 H amino acid substitution in influenza A ( H 1 N 1 ) pdm 09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors

F. Pozo, I. Casas, A. Lackenby, 2014 .

Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009–2010

R. Pebody, M. Zambon, A. Lackenby, 2011, Emerging infectious diseases.

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

Darren L. Smith, Evelien M. Adriaenssens, Gemma L. Kay, 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020

R. Myers, S. Ladhani, S. Hopkins, 2020, EClinicalMedicine.

Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons.

M. Zambon, A. Lackenby, Luís A. Santos, 2010, Antiviral research.

Late Ebola virus relapse causing meningoencephalitis: a case report

G. Wilkie, J. Hughes, R. Orton, 2016, The Lancet.

Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11.

R. Pebody, M. Galiano, A. Bermingham, 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway.

S. Goodbourn, J. McCauley, W. Barclay, 2006, Virology.

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Joshua B. Singer, Darren L. Smith, Shane A. McCarthy, 2021, The Lancet Infectious Diseases.

Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection.

A. Lackenby, S. Esposito, N. Principi, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

SARS-CoV-2 infection, antibody positivity and seroconversion rates in staff and students following full reopening of secondary schools in England: A prospective cohort study, September–December 2020

A. Brent, S. Ladhani, M. Zambon, 2021, eClinicalMedicine.

NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets.

W. Barclay, Konrad C. Bradley, A. Lackenby, 2016, The Journal of general virology.

Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes

R. Myers, S. Ladhani, S. Hopkins, 2020, Journal of Infection.

Favipiravir-resistant influenza A virus shows potential for transmission

A. Yan, D. Goldhill, Jie Zhou, 2020, bioRxiv.

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

William T. Harvey, Scott M Elliott, Robert M. Davies, 2022, Nature Microbiology.

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020

R. Webby, Dayan Wang, L. Gubareva, 2022, Antiviral research.

Virological surveillance of influenza viruses in the WHO European Region in 2019/20 – impact of the COVID-19 pandemic

J. Mossong, M. Castrucci, R. Pebody, 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England

H. Whitaker, S. Ladhani, M. Zambon, 2021, The Lancet Healthy Longevity.

Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.

B. Lina, R. Daniels, F. Pozo, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020

R. Myers, H. Whitaker, S. Ladhani, 2021, The Lancet Regional Health - Europe.

A case of avian influenza A(H5N1) in England, January 2022

I. Brown, J. Roberts, M. Zambon, 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Authors’ reply. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11

R. Pebody, M. Galiano, A. Bermingham, 2011 .

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017

Dayan Wang, S. Maurer-Stroh, L. Gubareva, 2018, Antiviral research.

Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise.

R. Daniels, J. McCauley, A. Lackenby, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.

M. Zambon, A. Hay, A. Lackenby, 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Development of a Reverse Genetics System Enabling theRescue of Recombinant Avian Influenza Virus A/Turkey/England/50-92/91 (H5N1)

J. McCauley, W. Barclay, A. Lackenby, 2007, Avian diseases.

Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort

D. Fleming, Gillian E. Smith, A. Elliot, 2013, The Journal of antimicrobial chemotherapy.

Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant

Graham W. Taylor, Joshua B. Singer, Darren L. Smith, 2021, Science.

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

D. A. Jackson, Graham W. Taylor, William L. Hamilton, 2020, Cell.

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Graham W. Taylor, Joshua B. Singer, Scott M Elliott, 2021, Nature.

Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08

A. Lackenby, K. Borgen, S. Hauge, 2009, Emerging infectious diseases.

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

P. Klenerman, T. Reynolds, M. Beekes, 2021, The Lancet.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016

Dayan Wang, L. Gubareva, S. Leang, 2017, Antiviral research.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015

Ha T. Nguyen, Dayan Wang, S. Maurer-Stroh, 2014, Antiviral research.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014

Dayan Wang, L. Gubareva, S. Leang, 2015, Antiviral research.

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.

Dayan Wang, L. Gubareva, A. Hurt, 2020, Antiviral research.

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.

A. Bermingham, M. Zambon, J. Ellis, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Transmitted and acquired oseltamivir resistance during the 2018-2019 influenza season.

T. Lam, J. Tang, J. Ellis, 2019, The Journal of infection.

The potential impact of neuraminidase inhibitor resistant influenza

A. Lackenby, C. Thompson, J. Democratis, 2008, Current opinion in infectious diseases.

Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England

S. Langan, P. Mangtani, A. Brent, 2021, PloS one.

SARS-CoV-2 evolution during treatment of chronic infection

Graham W. Taylor, William L. Hamilton, Joshua B. Singer, 2021, Nature.

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Scott L. Bain, A. Gibson, P. Klenerman, 2021, The Lancet.

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

William T. Harvey, Graham W. Taylor, William L. Hamilton, 2021, Cell Reports.

Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021–September 2022

M. Zambon, A. Lackenby, Susan Hopkins, 2022, Emerging infectious diseases.

Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning

William T. Harvey, Scott M Elliott, Kevin R. Cole, 2022, Scientific Reports.

Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission

Graham W. Taylor, Scott M Elliott, Jaime M. Tovar-Corona, 2022, Nature Communications.

Genomic reconstruction of the SARS-CoV-2 epidemic in England

William T. Harvey, William L. Hamilton, Richard J. Goater, 2021, Nature.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013

Dayan Wang, L. Gubareva, A. Hurt, 2014, Antiviral research.

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020

A. Charlett, S. Ladhani, M. Zambon, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

SARS-CoV-2 evolution during treatment of chronic infection

Graham W. Taylor, William L. Hamilton, Joshua B. Singer, 2021, Nature.

Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.

I. Donatelli, M. Zambon, A. Lackenby, 2011, Antiviral research.

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

N. Ferguson, A. Charlett, P. Freemont, 2021, The Lancet Infectious Diseases.

Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance

C. Donnelly, M. Galiano, W. Barclay, 2016, Scientific Reports.

Do point-of-care tests (POCTs) offer a new paradigm for the management of patients with influenza?

S. de Lusignan, R. Pebody, A. Elliot, 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Risk factors for fatality in Panton-Valentine leukocidin-producing Staphylococcus aureus pneumonia cases, England, 2012-2013.

N. Verlander, R. Pebody, A. Kearns, 2014, The Journal of infection.

NS1 Proteins of Avian Influenza A Viruses Can Act as Antagonists of the Human Alpha/Beta Interferon Response

S. Goodbourn, W. Barclay, J. McCauley, 2006, Journal of Virology.

Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing

D. Goldhill, P. Kellam, M. Galiano, 2018, Journal of Virology.

Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

William T. Harvey, Scott M Elliott, Kevin R. Cole, 2023, Journal of Hospital Infection.

Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England

A. Brent, S. Ladhani, M. Zambon, 2021, Journal of Infection.

Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

William T. Harvey, Scott M Elliott, Robert M. Davies, 2022, Nature Microbiology.

Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

M. Zambon, A. Hay, A. Lackenby, 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England

A. Brent, S. Ladhani, M. Zambon, 2021, eClinicalMedicine.

Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13

A. N. Robertson, D. Fleming, C. Robertson, 2013 .

Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.

R. Pebody, M. Galiano, A. Bermingham, 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19.

R. Pebody, H. Whitaker, M. Galiano, 2020, Vaccine.

Surveillance and outbreak reports A new laboratory-based surveillance system ( Respiratory DataMart System ) for influenza and other respiratory viruses in England : results and experience from 2009 to 2012

A. Bermingham, M. Zambon, J. Ellis, 2014 .

Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.

C. Fegan, M. Galiano, A. Lackenby, 2011, The Journal of infectious diseases.

Emergence of oseltamivir-resistant influenza A H1N1 virus during the 2007-2008 winter season in Luxembourg: clinical characteristics and epidemiology.

J. Mossong, V. Gregory, A. Lackenby, 2009, Antiviral research.

Community Transmission and Viral Load Kinetics of SARS-CoV-2 Delta (B.1.617.2)Variant in Vaccinated and Unvaccinated Individuals

N. Ferguson, A. Charlett, P. Freemont, 2021, Social Science Research Network.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Graham W. Taylor, William L. Hamilton, Joshua B. Singer, 2021, Nature.

Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation Sequencing

P. Kellam, M. Galiano, W. Barclay, 2018, bioRxiv.

Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness

W. Barclay, A. Lackenby, L. Hartgroves, 2010, The Journal of antimicrobial chemotherapy.

Monitoring the emergence of community transmission of influenza A/H1N1 2009 in England: a cross sectional opportunistic survey of self sampled telephone callers to NHS Direct

Chinelo Obi, Joanna Ellis, Ian Simms, 2009, BMJ : British Medical Journal.

Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients

J. A. Guerra-Assunção, S. Burns, A. Lackenby, 2023, Journal of Clinical Immunology.

Epidemiological report of pandemic (H1N1) 2009 in the UK, April 2009 - May 2010.

R. Pebody, A. Elliot, M. Galiano, 2010 .

of Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

D. A. Jackson, Graham W. Taylor, William L. Hamilton, 2021 .

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Joshua B. Singer, David A. Drew, Scott M Elliott, 2021, The Lancet. Public health.

Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13.

D. Fleming, N. Andrews, M. Zambon, 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.

A. Bermingham, M. Zambon, J. Ellis, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

Scott M Elliott, Kevin R. Cole, Robert M. Davies, 2022, Scientific Reports.